Author

Laurens Veltman

Finnish Red Cross

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

Erja KerkeläiD· 2 shared Farhana JahaniD· 2 shared Kim K. VettenrantaiD· 2 shared Seppo Ylä-HerttualaiD· 2 shared Anita LaitineniD· 1 shared Annu LuostarineniD· 1 shared Antti TuhkalaiD· 1 shared Diana SchenkweiniD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Erja KerkeläORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Efficient NK cell transduction with VSV-G-pseudotyped lentiviral vectors

Emmi Järvelä, Jan Koski, Farhana Jahan, Antti Tuhkala, Mira Saari, Manar Elmadani, Kari Salokas, Laurens Veltman, Lotta Andersson, Erja Kerkelä, Hekim Can, Marie C. Nyman, Seppo Ylä-Herttuala, Markku T Varjosalo, Diana Schenkwein, , Helka Göös

This study optimizes VSV-G-pseudotyped lentiviral transduction of NK cells by improving activation, construct design, and enhancer use, achieving high efficiency without compromising cell function.

Molecular Therapy Advances · May 5, 2026Peer-reviewedImmunology

Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts

Farhana Jahan, Leena Penna, Annu Luostarinen, Laurens Veltman, Heidi Hongisto, Kaarina Lähteenmäki, Sabine Müller, Seppo Ylä‐Herttuala, Matti O. Korhonen, Kim K. Vettenranta, Anita Laitinen, Urpu Salmenniemi, Erja Kerkelä

This paper describes a GMP-compliant protocol for producing potent NK cells against AML and neuroblastoma using an automated platform, showing increased activation and killing efficacy.

Scientific Reports · Nov 4, 2024Peer-reviewedImmunology